Kuwait Medical Journal, cilt.2023, sa.2, ss.139-144, 2023 (SCI-Expanded)
Objectives: This study aimed to evaluate non-dipper hypertension for risk of contrast-induced nephropathy in patients with coronary artery disease undergoing percutaneous coronary intervention. Design: Prospective study Setting: Department of Cardiology, Erciyes University Medical Faculty Subject: This study prospectively included a total of 161 patients (108 patients with dipper, 53 with non-dipper). Blood pressure (BP) measurements in the clinic were performed using sphygmomanometer. If the mean BP measured during night wass less than 10% lower than the mean daytime measurement, these individuals were “non-dipper”. Intervention: Negative efficacy of non-dipper hypertension on renal Main Outcome Measure: Patients were evaluated as contrast-induced nephropathy according to 25% increase creatinine level. Results: When both groups were compared for the development of contrast-induced nephropathy, it was detected in 11 (20%) patients in the non-dipper group and in 8 (7%, P=0.016) patients in the dipper group. Mehran risk scoring predictor of contrast nephropathy revealed a significant difference between hypertension and diabetes mellitus (DM) in the groups, except for non-dipper hypertension (P=0.016 and P=0.028, respectively). The effect of non-dipper hypertension was significant in multivariant analysis among the parameters affecting contrast nephropathy (P=0.023, OR: 0.99-7.984). Conclusions: Non-dipper hypertension is a risk factor in the development of contrast-induced nephropathy, independently of the risk factors of the Mehran.